Shortly after the Securities and Exchange Commission launched an investigation into accounting at Biovail Corp. in March 2005, the company turned to Howrey for help. By Monday, when the Canadian pharmaceutical company announced its settlement with the SEC, Howrey had dropped out of the picture and Curtis, Mallet-Prevost, Colt and Mosle had slipped in.
Partner T. Barry Kingham led the Curtis, Mallet-Prevost team that negotiated the settlement, according to SEC attorney Robert Keyes. The SEC was investigating Biovail’s accounting and financial disclosure practices between 2001 and 2003. Biovail agreed to pay $10 million and to retain an independent consultant to examine its accounting practices. The company did not admit to any wrongdoing.
